@article{5cea60043be84bc8a94f58e659290d3e,
title = "Short Communication: Impact of Fat Changes on the Effect of Protease Inhibitors on Lumbar Spine Bone Mineral Density Changes with Antiretroviral Therapy Initiation",
abstract = "People living with HIV (PLWH) who are on protease inhibitor (PI)-containing regimens have been shown to have increases in visceral adipose tissue (VAT) and a greater decrease in spine bone mineral density (BMD) than those receiving non-PI regimens when initiating treatment. This increase in VAT has been hypothesized to falsely lower spine BMD measured via dual-energy X-ray absorptiometry, suggesting that the PI-associated BMD loss is an artefact rather than real. To test this, data collected from two completed 96-week clinical trials, AIDS Clinical Trial Group studies A5224s and A5260s, of antiretroviral therapy-naive PLWH initiating treatment with PI and non-PI-containing regimens were analyzed comparing VAT accumulation and spine BMD loss. Results showed no significant decrease in spine BMD in persons in the highest quartile (Q4) of VAT gain versus the rest of the study population (Q1-3) in either the PI and non-PI arms, suggesting that PI-associated BMD loss is not likely to be an artefact of overlying VAT. ",
keywords = "bone mineral density, human immunodeficiency virus, protease inhibitor, visceral adipose tissue",
author = "Joshua Garza and Carlee Moser and Kitch, {Douglas W.} and Currier, {Judith S.} and Dub{\'e}, {Michael P.} and James Stein and Grace McComsey and Brown, {Todd T.}",
note = "Funding Information: T.T.B. has served as a consultant for Merck, Gilead, ViiV Healthcare, and Theratechnologies. J.S.C. has received research funding from Theratechnologies. M.P.D. has received research funding from Gilead, Theratechnologies, and ViiV. J.S. serves on a Data Safety Monitoring Board for Lilly and has a research grant from Gilead. G.M. has served as a consultant for Merck, ViiV, and Gilead and has received research grants from Roche, Merck, Gilead, Tetraphase, and Astellas. C.M., J.G., and D.W.K. have no conflict of interest disclosures. This study was presented at the 18th International Workshop on Comorbidities and Adverse Drug Reactions in HIV, New York, 2016. Funding Information: This research was supported by NIH grants HL095132, HL095126, AI 068636, AI068634, AI69471, and AI56933. T.T.B. is supported, in part, by NIH/NIAID K24 AI120834.The project described was supported by award no. U01AI068636 from the National Institute of Allergy and Infectious Diseases and supported by National Institute of Mental Health (NIMH), National Institute of Dental and Craniofacial Research (NIDCR). The protocol received support from the AIDS Clinical Trials Group, the Site Data Management Center grant of UM1AI68634 and the ACTG clinical research sites. Publisher Copyright: {\textcopyright} Copyright 2020, Mary Ann Liebert, Inc.",
year = "2020",
month = oct,
day = "1",
doi = "10.1089/aid.2019.0290",
language = "English (US)",
volume = "36",
pages = "831--834",
journal = "AIDS Research and Human Retroviruses",
issn = "0889-2229",
publisher = "Mary Ann Liebert Inc.",
number = "10",
}